Investors
Financial Calendar
Q3 2022 Business and Financial Highlights
Half-Year Results 2022
Annual General Meeting 2022
Q1 2022 Business and Financial Highlights
Full Year Results & Publication Annual Report 2021
BioSenic was formed through a reverse merger between Bone Therapeutics and Medsenic. All financial information can be found below.
Shareholder Information
SHAREHOLDER STRUCTURE
SHARE INFORMATION
BioSenic's shares were listed on the regulated market of Euronext Brussels and Euronext Paris on February 6, 2015 under the symbol BIOS.
As of 20-02-2023, BioSenic has a total number of 124,008,857 oustanding shares.
ANALYSTS COVERAGE
Portzamparc
Analyst : Clément Bassat
Price Target : 0,21 € on 14/02/2023
Gilbert Dupont
Analyst : Pierre-Alexandre Desir
Price Target : 0,52 € on 14/02/2023
Corporate Governance
IR Contact
Alexia Rieger, CIRO, Chief Investor Relation Officer
BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
investorrelations@biosenic.com
BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact